JP2015514090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514090A5 JP2015514090A5 JP2015503464A JP2015503464A JP2015514090A5 JP 2015514090 A5 JP2015514090 A5 JP 2015514090A5 JP 2015503464 A JP2015503464 A JP 2015503464A JP 2015503464 A JP2015503464 A JP 2015503464A JP 2015514090 A5 JP2015514090 A5 JP 2015514090A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- seq
- amino acid
- antibody
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615539P | 2012-03-26 | 2012-03-26 | |
| US61/615,539 | 2012-03-26 | ||
| FR1351013 | 2013-02-06 | ||
| FR1351013 | 2013-02-06 | ||
| PCT/US2013/033881 WO2013148686A2 (en) | 2012-03-26 | 2013-03-26 | Stable igg4 binding agent formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017205914A Division JP6820823B2 (ja) | 2012-03-26 | 2017-10-25 | 安定なＩｇＧ４に基づく結合剤の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514090A JP2015514090A (ja) | 2015-05-18 |
| JP2015514090A5 true JP2015514090A5 (enExample) | 2016-03-17 |
| JP6265970B2 JP6265970B2 (ja) | 2018-01-24 |
Family
ID=49261390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503464A Active JP6265970B2 (ja) | 2012-03-26 | 2013-03-26 | 安定なＩｇＧ４に基づく結合剤の製剤 |
Country Status (7)
| Country | Link |
|---|---|
| EP (3) | EP2830658B1 (enExample) |
| JP (1) | JP6265970B2 (enExample) |
| BR (2) | BR112014023952B1 (enExample) |
| CA (3) | CA2868401C (enExample) |
| PL (1) | PL2830658T3 (enExample) |
| RU (1) | RU2644214C2 (enExample) |
| WO (1) | WO2013148686A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3297654T3 (pl) | 2015-05-22 | 2021-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Leczenie pobariatrycznej hipoglikemii eksendyną (9-39) |
| GB201608323D0 (en) * | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| CN107446044B (zh) * | 2016-05-30 | 2021-04-30 | 越海百奥药业(绍兴)有限公司 | 一种纯化抗体的方法及所用缓冲液 |
| TWI760345B (zh) * | 2016-07-05 | 2022-04-11 | 法商賽諾菲公司 | 抗體調配物 |
| DK3481420T3 (da) * | 2016-07-05 | 2025-11-03 | Sanofi Sa | Antistofformuleringer |
| US20190359930A1 (en) * | 2016-11-11 | 2019-11-28 | Bayer Aktiengesellschaft | Method for sampling fluid streams for monitoring contaminants in a continuous flow |
| SMT202500120T1 (it) * | 2016-11-21 | 2025-05-12 | Amylyx Pharmaceuticals Inc | Formulazioni tamponate di esendina (9-39) |
| GB201701194D0 (en) * | 2017-01-24 | 2017-03-08 | Capella Bioscience Ltd | Antigen binding molecules that bind light |
| JP2020509025A (ja) * | 2017-03-01 | 2020-03-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | モノクローナル抗体製剤 |
| TWI911431B (zh) | 2017-03-01 | 2026-01-11 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| US11312781B2 (en) | 2018-01-24 | 2022-04-26 | Capella Bioscience Ltd. | Antigen binding molecules that bind LIGHT |
| JP2024502825A (ja) * | 2020-12-30 | 2024-01-23 | エーマックス バイオ， インコーポレイテッド | 抗体の局所的延長放出 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2966592B2 (ja) * | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO2003068260A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| CN103040732B (zh) * | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| WO2006042333A2 (en) | 2004-10-12 | 2006-04-20 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP5231810B2 (ja) * | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| SMP200800064B (it) * | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| EP2484696B1 (en) | 2006-08-28 | 2017-08-16 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic hLIGHT-specific human monoclonal antibodies |
| CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| EP2195023B1 (en) * | 2007-08-29 | 2018-03-07 | Sanofi | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| AU2012250924B2 (en) * | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
-
2013
- 2013-03-26 JP JP2015503464A patent/JP6265970B2/ja active Active
- 2013-03-26 BR BR112014023952-5A patent/BR112014023952B1/pt active IP Right Grant
- 2013-03-26 EP EP13714505.8A patent/EP2830658B1/en active Active
- 2013-03-26 EP EP18190556.3A patent/EP3431104B1/en active Active
- 2013-03-26 WO PCT/US2013/033881 patent/WO2013148686A2/en not_active Ceased
- 2013-03-26 CA CA2868401A patent/CA2868401C/en active Active
- 2013-03-26 PL PL13714505T patent/PL2830658T3/pl unknown
- 2013-03-26 BR BR122019026701-4A patent/BR122019026701B1/pt active IP Right Grant
- 2013-03-26 CA CA3123252A patent/CA3123252C/en active Active
- 2013-03-26 CA CA3204402A patent/CA3204402A1/en active Pending
- 2013-03-26 EP EP25150972.5A patent/EP4527855A3/en active Pending
- 2013-03-26 RU RU2014142990A patent/RU2644214C2/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014142990A (ru) | Стабильные препараты связывающего средства на основе igg4 | |
| ES2959257T3 (es) | Composición farmacéutica que comprende construcciones de anticuerpo biespecífico | |
| CN114007647B (zh) | 含有抗angptl3抗体的稳定制剂 | |
| JP2024012308A (ja) | 抗ｌａｇ－３抗体の投薬量レジメンおよびその使用 | |
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| ES2783448T3 (es) | Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28 | |
| CN106659785B (zh) | 包含gm-csf中和化合物的液体制剂 | |
| JP2013543505A5 (enExample) | ||
| HRP20251036T1 (hr) | Stabilna formulacija antitijela | |
| KR102885113B1 (ko) | 항-rsv 항체의 제제 및 그의 사용 방법 | |
| JP2018502060A5 (enExample) | ||
| JP2016535020A5 (enExample) | ||
| RU2016119755A (ru) | Стабильные водные составы на основе антител | |
| JP2015521593A5 (enExample) | ||
| JP2016537340A5 (enExample) | ||
| FI3209681T3 (fi) | Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä | |
| MX2013003795A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
| RU2019102943A (ru) | Составы на основе антитела | |
| SI2658575T1 (en) | A pharmaceutical formulation comprising a biopharmaceutical | |
| US11141479B2 (en) | Stable anti-OSMR antibody formulation | |
| JP2015515492A5 (enExample) | ||
| RU2012139829A (ru) | АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8 | |
| JP2019537617A5 (enExample) | ||
| JP2022526292A5 (enExample) | ||
| JP2018519834A (ja) | ヒトＦｃ受容体に結合する融合タンパク質 |